Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 86

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 86
---
 (CAGR) of 12% from 2025 to 2034, reaching around $71.5 billion by 2031 (based on estimates from sources like Grand View Research and iHealthcareAnalyst). While this encompasses all cessation aids, a portion of this market addresses weight gain management, though specific figures for this subset are not isolated in most reports. The nicotine replacement therapy (“NRT”) market, a significant segment of smoking cessation, was valued at $2.94 billion in 2024 and is expected to reach $4.27 billion by 2032, with a CAGR of 4.8% (Fortune Business Insights). Drugs and therapies within this segment often influence weight gain outcomes (Source: https://pmc.ncbi.nlm.nih.govand https://www.gminsights.com).

Figure:Estimates of the Smoking Cessation Target Population.

| 46 |

Trends Driving the Market

Increased recognition of smoking-related health issues (e.g., lung cancer, cardiovascular disease) and the associated challenge of weight gain post-cessation are driving demand for integrated solutions. Weight gain, averaging 4-5 kg in the first year after quitting, is a well-documented barrier to cessation success, prompting interest in dual-purpose interventions. Governmental and international initiatives (e.g., WHO’s Framework Convention on Tobacco Control) and awareness campaigns are boosting the adoption of cessation aids, including those that mitigate weight gain. For instance, the prevalence of smoking remains high globally (1.3 billion tobacco users per WHO 2023 data), amplifying the need for effective cessation strategies. There is a trend toward combining smoking cessation with weight control strategies, as many quitters cite weight gain as a relapse trigger. This has spurred research into drugs that address both nicotine withdrawal and metabolic changes. Clinical studies and product launches by key players (e.g., Achieve Life Sciences’ cytisinicline trial in May 2024) are expanding options, though most focus on cessation efficacy rather than weight gain alone. However, the side effect of weight gain is increasingly considered in trial designs.

Market Challenges

Some cessation drugs have side effects that complicate weight management, potentially limiting their appeal. While short-term weight gain prevention is achievable, sustaining these effects beyond 12 months remains a challenge, influencing market growth dynamics.

Competitors for Smoking Cessation Products

There are several potential pharmaceutical companies that we deem as competitors actively developing smoking cessation products.. These companies may have products that are more advanced in their development and FDA-process than